SCHEMBL1416554

SCHEMBL1416554

Fc1cccc(-c2cc[c]s2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.47
HSD17B2 P37059 2/20 0.47
TAAR1 Q96RJ0 3/20 0.41
ESR2 Q92731 1/20 0.41
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
NFE2L2 Q16236 1/20 0.38
NPC1 O15118 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
IDO1 P14902 2/20 0.36
NOTUM Q6P988 1/20 0.36
PTPN1 P18031 1/20 0.36
ESRRG P62508 1/20 0.35
CHRNB4 P30926 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2752663 0.82 HSD17B1 (0.35) HSD17B1HSD17B2NOTUM
SCHEMBL1415990 0.79 HSD17B1 (0.36) HSD17B1HSD17B2KDM4EMEN1MAPT
SCHEMBL385688 0.79 ALDH1A1 (0.38) HSD17B1HSD17B2TAAR1ESR2MEN1
SCHEMBL4897549 0.78 NOTUM (0.41) NPC1RAB9AIDO1NOTUM
SCHEMBL1416520 0.77 ALOX5 (0.40) TAAR1ESR2NPC1NFKB1RAB9A
SCHEMBL1416534 0.77 ACHE (0.41) HSD17B1HSD17B2MEN1KMT2ANPC1
SCHEMBL4410865 0.75 ALDH1A1 (0.41) HSD17B1HSD17B2TAAR1MEN1KMT2A
SCHEMBL1416583 0.74 HSD17B1 (0.42) HSD17B1HSD17B2KDM4ERAB9ANOTUM
SCHEMBL6017913 0.74 NISCH (0.38) HSD17B1HSD17B2NISCH
SCHEMBL1416379 0.73 DYRK1A (0.46) HSD17B1HSD17B2MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1829721-A Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor ASTRAZENECA AB (SE) 2006-09-06 CN claimed
US-20060178403-A1 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto NEUROCRINE BIOSCIENCES, INC. (US) 2006-08-10 US claimed
CN-1207056-C Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors CEPHALEN INC (US) 2005-06-22 CN claimed
WO-2004081005-A1 MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO NEUROCRINE BIOSCIENCES, INC. (US) 2004-09-23 WO claimed
EP-1161438-A1 6-O-SUBSTITUTED MACROLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 2001-12-12 EP claimed
WO-2000055168-A1 6-O-SUBSTITUTED MACROLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 2000-09-21 WO claimed
EP-2066643-B1 PYRIDAZIN-4-YLMETHYL-SULFONAMIDES USED AS FUNGICIDES AND AGAINST ARTHROPODS BASF SE (DE) 2011-03-16 EP disclosed
US-20100077512-A1 Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods BASF SE (DE) 2010-03-25 US disclosed
CN-1829721-A Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor ASTRAZENECA AB (SE) 2006-09-06 CN disclosed
US-20060178403-A1 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto NEUROCRINE BIOSCIENCES, INC. (US) 2006-08-10 US disclosed
CN-1207056-C Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors CEPHALEN INC (US) 2005-06-22 CN disclosed
EP-1161438-A1 6-O-SUBSTITUTED MACROLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 2001-12-12 EP disclosed
CN-1274288-A Peptide-containing & alpha, -ketoamide cysteine and serine protease inhibitors CEPHALEN INC (US) 2000-11-22 CN disclosed
WO-2000055168-A1 6-O-SUBSTITUTED MACROLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100077512-A1 Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods PIR, PRDX4, PRDX2 HSD17B1 3589/4885HSD17B2 3363/4885TAAR1 1948/4885
US-20060178403-A1 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto MCHR1, MCHR2, MC1R HSD17B1 335/4885HSD17B2 314/4885TAAR1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.